Although insulin resistance and increased oxidative stress are believed to be major risk factors for the progression to NASH many agents, including insulin sensitizers, have been evaluated with disappointing results in the management of NASH. This evidence concerns the gene INS and metabolic dysfunction-associated steatohepatitis.